Rishi J Desai1, Daniel H Solomon, Sebastian Schneeweiss, Goodarz Danaei, Katherine P Liao, Seoyoung C Kim. 1. From the aDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School, Boston, MA; bDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA; and cDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA.
Abstract
OBJECTIVE: To compare the risk of incident hypertension between initiators of tumor necrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritis patients taking methotrexate monotherapy. METHODS: We conducted a cohort study using insurance claims data (2001-2012) from the US. We identified initiators of use of either TNF-α inhibitors or nonbiologics. Subsequent exposure to these agents was measured monthly in a time-varying manner. The outcome of interest was incident hypertension, defined by a diagnosis and a prescription for an antihypertensive drug. Marginal structural models estimated hazard ratios (HRs) adjusted for both baseline and time-varying confounders. To validate the primary analysis, we designed a verification analysis to evaluate a known association between leflunomide (a nonbiologic disease modifying agent) and hypertension. RESULTS: We identified 4,822 initiations of TNF-α inhibitor use and 2,400 of nonbiologic use. Crude incidence rates of hypertension per 1,000 person-years of follow-up were 36 (95% CI [confidence interval]: 32, 41) for the TNF-α inhibitor group and 42 (95% CI: 34, 51) for the nonbiologics group. The crude HR of TNF-α inhibitors versus nonbiologics for the risk of incident hypertension was 0.85 (95% CI: 0.67, 1.1). After adjusting for both baseline and time-varying covariates using marginal structural models, the HR was 0.95 (95% CI: 0.74, 1.2). In the verification analysis, the adjusted HR of incident hypertension was 2.3 (95% CI: 1.7, 3.0) in leflunomide initiators compared with methotrexate initiators. CONCLUSION: Treatment with TNF-α inhibitors was not associated with a reduced risk of incident hypertension compared with nonbiologics in rheumatoid arthritis patients.See Video Abstract at http://links.lww.com/EDE/B36.
OBJECTIVE: To compare the risk of incident hypertension between initiators of tumornecrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritispatients taking methotrexate monotherapy. METHODS: We conducted a cohort study using insurance claims data (2001-2012) from the US. We identified initiators of use of either TNF-α inhibitors or nonbiologics. Subsequent exposure to these agents was measured monthly in a time-varying manner. The outcome of interest was incident hypertension, defined by a diagnosis and a prescription for an antihypertensive drug. Marginal structural models estimated hazard ratios (HRs) adjusted for both baseline and time-varying confounders. To validate the primary analysis, we designed a verification analysis to evaluate a known association between leflunomide (a nonbiologic disease modifying agent) and hypertension. RESULTS: We identified 4,822 initiations of TNF-α inhibitor use and 2,400 of nonbiologic use. Crude incidence rates of hypertension per 1,000 person-years of follow-up were 36 (95% CI [confidence interval]: 32, 41) for the TNF-α inhibitor group and 42 (95% CI: 34, 51) for the nonbiologics group. The crude HR of TNF-α inhibitors versus nonbiologics for the risk of incident hypertension was 0.85 (95% CI: 0.67, 1.1). After adjusting for both baseline and time-varying covariates using marginal structural models, the HR was 0.95 (95% CI: 0.74, 1.2). In the verification analysis, the adjusted HR of incident hypertension was 2.3 (95% CI: 1.7, 3.0) in leflunomide initiators compared with methotrexate initiators. CONCLUSION: Treatment with TNF-α inhibitors was not associated with a reduced risk of incident hypertension compared with nonbiologics in rheumatoid arthritispatients.See Video Abstract at http://links.lww.com/EDE/B36.
Authors: A Sandoo; V F Panoulas; T E Toms; J P Smith; A Stavropoulos-Kalinoglou; G S Metsios; A Y Gasparyan; D Carroll; J J C S Veldhuijzen van Zanten; G D Kitas Journal: J Hum Hypertens Date: 2011-04-28 Impact factor: 3.012
Authors: Michael F Bullano; Siddhesh Kamat; Vincent J Willey; Suna Barlas; Douglas J Watson; Susan K Brenneman Journal: Med Care Date: 2006-05 Impact factor: 2.983
Authors: Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker Journal: JAMA Date: 2003-12-10 Impact factor: 56.272
Authors: Julia Spoendlin; Julie M Paik; T Tsacogianis; Seoyoung C Kim; Sebastian Schneeweiss; Rishi J Desai Journal: JAMA Intern Med Date: 2019-06-01 Impact factor: 21.873
Authors: Jean W Liew; Michael M Ward; John D Reveille; Michael Weisman; Matthew A Brown; MinJae Lee; Mohammed Rahbar; Susan R Heckbert; Lianne S Gensler Journal: Arthritis Care Res (Hoboken) Date: 2020-11 Impact factor: 4.794
Authors: Malin C Erlandsson; Lovisa Lyngfelt; N David Åberg; Caroline Wasén; Rachelle A Espino; Sofia Töyrä Silfverswärd; Mitra Nadali; Katharina Jood; Karin M E Andersson; Rille Pullerits; Maria I Bokarewa Journal: BMC Med Date: 2019-07-22 Impact factor: 8.775